EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy

Wenyan Su, Jianyi Li, Jinzhao Men, Shuo Zhong, Yunzhao Wang, Yao Zhang, Liang Xu, Jie Gao, Dan Liu, Rong Wang, Jing Sun, Haiping Wang

Clinical Kidney Journal · 01.05.2025 · 18 (5)

DOI: 10.1093/ckj/sfaf026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 01.05.2025. Verfasst von Wenyan Su und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Shandong Province, Youth Science Foundation of Shandong First Medical University, Jinan Clinical Medicine Science and Technology Innovation Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical experience with obinutuzumab in patients with rituximab-refractory phospholipase A2 receptor (PLA2R)-associated membranous nephropathy remains limited. This study aimed to evaluate the efficacy and safety of obinutuzumab in treating patients with rituximab-refractory PLA2R-associated membranous nephropathy.

Methods

A single-center retrospective study was conducted on 20 patients with rituximab-refractory PLA2R-associated membranous nephropathy who received two doses of 1 g obinutuzumab, administered 2 weeks apart. At 6 months, patients with urinary protein levels exceeding 3.5 g/d received an additional dose of 1–2 g obinutuzumab. The primary clinical outcome was a composite measure of complete or partial remission during follow-up. Continuous secondary outcomes included 24-hour urinary protein, serum albumin, serum creatinine, serum anti-PLA2R levels, and CD19 B-cell counts at the time of obinutuzumab infusion, at 3 months, and at the last visit.

Results

A total of 20 patients with clinical manifestations of nephrotic syndrome were included in this study, with a median follow-up period of 9 months. The mean age of the patients was 46.25 ± 13.05 years. At a median follow-up of 4.50 months (3.00–8.25 months) after obinutuzumab therapy, remission was achieved in 16 patients. Two patients (10%) achieved complete remission, while 14 (70%) attained partial remission. At baseline, 16 out of 20 patients tested positive for serum anti-PLA2R antibodies, and immunological remission was observed in 11 of these 16 patients during follow-up. All patients experienced B-lymphocyte depletion within 1 month after receiving obinutuzumab infusion and maintained this depletion at 3 months. B-lymphocyte reconstitution was noted in 4 out of 20 patients (20%) at 6 months. No patients experienced fatal adverse events.

Conclusion

Obinutuzumab mainly induces short-term partial remissions in patients with rituximab-refractory primary membranous nephropathy, which may be related to the short follow-up period. However, this study demonstrates that obinutuzumab is an effective and safe treatment for rituximab-refractory PLA2R-associated membranous nephropathy.

Schlagwörter

Stichwörter der Autor:innen

M-type phospholipase A2 receptormembranous nephropathyobinutuzumabrituximab refractory

Autor:innen und Institutionen

  • Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
  • Department of Urology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Organ Transplantation and Nephrosis,…
  • Department of Bioinformatics Specialization, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
  • Department of Nephrology, Yanzhou District People's Hospital, Jining, China.

Förderung

  • Natural Science Foundation of Shandong Province
  • Youth Science Foundation of Shandong First Medical University
  • Jinan Clinical Medicine Science and Technology Innovation Projects
  • Shandong Provincial Science and Technology Development Plan Projects

Zitieren

APA

Su, W., Li, J., Men, J., Zhong, S., Wang, Y., Zhang, Y., Xu, L., Gao, J., Liu, D., Wang, R., Sun, J., & Wang, H. (2025). Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy. Clinical Kidney Journal, 18(5). https://doi.org/10.1093/ckj/sfaf026

Vancouver

Su W, Li J, Men J, Zhong S, Wang Y, Zhang Y, et al. Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy. Clinical Kidney Journal. 2025;18(5). doi:10.1093/ckj/sfaf026

BibTeX
@article{Su2025,
  author = {Su, Wenyan and Li, Jianyi and Men, Jinzhao and Zhong, Shuo and Wang, Yunzhao and Zhang, Yao and Xu, Liang and Gao, Jie and Liu, Dan and Wang, Rong and Sun, Jing and Wang, Haiping},
  title = {Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {5},
  doi = {10.1093/ckj/sfaf026}
}
Kostenlos starten →